Mimedx Group, Inc. (MDXG): Parker H Petit , CEO of Mimedx Group, Inc. purchased 50,000 shares on May 12, 2016. The Insider buying transaction was reported by the company on May 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $6.74 per share for a total value of $337,000.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Nov 16, 2015, Charles Robert Evans (director) purchased 10,000 shares at $7.84 per share price.On Nov 10, 2015, Parker H Petit (CEO) purchased 131,925 shares at $7.58 per share price.Also, On Oct 30, 2015, Alexandra O Haden (General Counsel & Secretary) purchased 4,150 shares at $7.92 per share price.On May 29, 2015, Larry W Papasan (director) sold 5,958 shares at $10.09 per share price.
Shares of MiMedx Group Inc (MDXG) ended Tuesday, May 10, 2016 session in red amid volatile trading. The shares closed down -0.155 points or -2.17% at $7 with 9,16,707 shares getting traded. Post opening the session at $7.18, the shares hit an intraday low of $6.94 and an intraday high of $7.29 and the price vacillated in this range throughout the day. The company has a market cap of $755 M and the number of outstanding shares has been calculated to be 10,78,10,490 shares. The 52-week high of MiMedx Group Inc is $13.2 and the 52-week low is $6.71.
Company has been under the radar of several Street Analysts.MiMedx Group Inc is Downgraded by First Analysis Sec to Equal-Weight while Lowering the Price Target of the company shares to $ 9 from a previous price target of $14 . Earlier the firm had a rating of Overweight on the company shares. The Rating was issued on Apr 27, 2016.MiMedx Group Inc is Reiterated by Needham to Strong Buy while Lowering the Price Target of the company shares to $ 12 from a previous price target of $13 . The Rating was issued on Apr 12, 2016.MiMedx Group Inc is Reiterated by Needham to Strong Buy while Lowering the Price Target of the company shares to $ 12 from a previous price target of $13 . The Rating was issued on Apr 11, 2016.
MiMedx Group Inc. (MiMedx) is an integrated developer manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant which is referred as an allograft. MiMedx is the supplier of amniotic tissue having supplied over 350000 allografts for application in the Wound Care Surgical Sports Medicine Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.